COVID 19-Caregivers IGg Seroconversion (CoSigS)
Comparison of the Proportion of Covid19 Seroconversion of Caregivers Working or Not in the COVID Sector
According to recent publications, the percentage of caregivers infected with COVID 19 is evaluated between 10 and 30% . This great variability is due, on the one hand to the intensity of the influx of covid plus patients and, on the other hand, to the disparity in the preparation of caregivers in the face of this emergency. Indeed, we can understand that the strict application of hygiene rules can be faulted in the face of the volume of patients, the lack of protective equipment and the lack of specific training for caregivers in this area. As a result, within healthcare teams, there are many questions that generate anxiety: will I be able to provide care properly while protecting myself from the risk of contamination? This anxiety is also present and sometimes manifests itself aggressively in the entourage or in the vicinity of caregivers, due to lack of scientific data adapted to the local ecology of the crisis.
Thus, the aim of this study is to show that the risk for caregivers of being contaminated by COVID in an area dedicated to COVID positive patients is no higher than being a caregiver in a non-COVID area that he either in the adult or pediatric sector.
研究概览
研究类型
联系人和位置
学习地点
-
-
-
Limoges、法国
- CHU de Limoges
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
取样方法
研究人群
Caregivers staff assigned to a non-intensive care COVID service
- Or caregiversg staff assigned to a non-COVID adult service
- Or caregivers staff assigned to a non-COVID pediatric service
描述
Inclusion Criteria:
- caregivers staff assigned to a non-intensive care COVID service
- or caregivers staff assigned to a non-COVID adult service
- or caregivers staff assigned to a non-COVID pediatric service
- Age > = 18 years old
- With health insurance
- Express consent
Exclusion Criteria:
- Protected persons
- Refusal to participate
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Covid area
|
3 blood samples (D0, D15 and D30) will be taken from each participant
|
|
Non-Covid area
|
3 blood samples (D0, D15 and D30) will be taken from each participant
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Seroconversion
大体时间:Day1
|
Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
|
Day1
|
|
Seroconversion
大体时间:Day 15
|
Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
|
Day 15
|
|
Seroconversion
大体时间:Day 30
|
Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
|
Day 30
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.